Publications

  1. Haffar S, Bazerbachi F, Leise MD, Dillon JJ, Albright RC, Murad MH, Kamath PS, Watt KD. Systematic review with meta-analysis: the association between hepatitis E seroprevalence and haemodialysis. Aliment Pharmacol Ther. 2017 Nov; 46 (9):790-799 Epub 2017 Sept 04
    View PubMed
  2. Bazerbachi F, Conboy EE, Mounajjed T, Watt KD, Babovic-Vuksanovic D, Patel SB, Kamath PS. Cryptogenic Cirrhosis and Sitosterolemia: A Treatable Disease If Identified but Fatal If Missed. Ann Hepatol. 2017 Oct 16; 16 (6):970-978
    View PubMed
  3. Bhanji RA, Carey EJ, Yang L, Watt KD. The Long Winding Road to Transplant: How Sarcopenia and Debility Impact Morbidity and Mortality on the Waitlist. Clin Gastroenterol Hepatol. 2017 Oct; 15 (10):1492-1497 Epub 2017 Apr 08
    View PubMed
  4. Bhanji RA, Watt KD. Fatty allograft and cardiovascular outcomes after liver transplantation. Liver Transpl. 2017 Oct; 23 (S1):S76-S80
    View PubMed
  5. Doycheva I, Issa D, Watt KD, Lopez R, Rifai G, Alkhouri N. Nonalcoholic Steatohepatitis is the Most Rapidly Increasing Indication for Liver Transplantation in Young Adults in the United States. J Clin Gastroenterol. 2017 Sep 28 Epub 2017 Sept 28
    View PubMed
  6. Welch BT, Schmitz JJ, Kurup AN, Atwell TD, Callstrom MR, Frey G, Paz-Fumagalli R, Allen A, Watt K, Heimbach J, Schmit GD. Feasibility and outcomes of percutaneous thermal ablation of hepatocellular carcinoma in a transplanted allograft. Abdom Radiol (NY). 2017 Sep 21 Epub 2017 Sept 21
    View PubMed
  7. Bhanji RA, Narayanan P, Allen AM, Malhi H, Watt KD. Sarcopenia in hiding: The risk and consequence of underestimating muscle dysfunction in nonalcoholic steatohepatitis. Hepatology. 2017 Aug 04 [Epub ahead of print]
    View PubMed
  8. Mouchli MA, Singh S, Loftus EV Jr, Boardman L, Talwalkar J, Rosen CB, Heimbach JK, Wiesner RH, Hasan B, Poterucha JJ, Watt KD, Kymberly WD. Risk Factors and Outcomes of De Novo Cancers (Excluding Nonmelanoma Skin Cancer) After Liver Transplantation for Primary Sclerosing Cholangitis. Transplantation. 2017 Aug; 101 (8):1859-1866
    View PubMed
  9. Bazerbachi F, Leise MD, Watt KD, Murad MH, Prokop LJ, Haffar S. Systematic review of mixed cryoglobulinemia associated with hepatitis E virus infection: association or causation? Gastroenterol Rep (Oxf). 2017 Aug; 5 (3):178-184 Epub 2017 May 19
    View PubMed
  10. Kittanamongkolchai W, El-Zoghby ZM, Eileen Hay J, Wiesner RH, Kamath PS, LaRusso NF, Watt KD, Cramer CH, Leung N. Charcoal hemoperfusion in the treatment of medically refractory pruritus in cholestatic liver disease. Hepatol Int. 2017 Jul; 11 (4):384-389 Epub 2016 Dec 08
    View PubMed
  11. Bhanji RA, Carey EJ, Watt KD. Review article: maximising quality of life while aspiring for quantity of life in end-stage liver disease. Aliment Pharmacol Ther. 2017 Jul; 46: (1)16-25.
    View PubMed
  12. Doycheva I, Watt KD, Alkhouri N. Nonalcoholic fatty liver disease in adolescents and young adults: The next frontier in the epidemic. Hepatology. 2017 Jun; 65 (6):2100-2109 Epub 2017 Apr 28
    View PubMed
  13. Yang JD, Larson JJ, Watt KD, Allen AM, Wiesner RH, Gores GJ, Roberts LR, Heimbach JA, Leise MD. Hepatocellular Carcinoma Is the Most Common Indication for Liver Transplantation and Placement on the Waitlist in the United States. Clin Gastroenterol Hepatol. 2017 May; 15: (5)767-775.e3.
    View PubMed
  14. Doycheva I, Watt KD, Rifai G, Abou Mrad R, Lopez R, Zein NN, Carey WD, Alkhouri N. Increasing Burden of Chronic Liver Disease Among Adolescents and Young Adults in the USA: A Silent Epidemic. Dig Dis Sci. 2017 May; 62: (5)1373-1380.
    View PubMed
  15. Kabbany MN, Conjeevaram Selvakumar PK, Watt K, Lopez R, Akras Z, Zein N, Carey W, Alkhouri N. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data. Am J Gastroenterol. 2017 Apr; 112: (4)581-587.
    View PubMed
  16. Doycheva I, Shaker M, Allende D, Lopez R, Watt KD, Alkhouri N. Low Utility of Noninvasive Fibrosis Scores in Young Adults with Nonalcoholic Fatty Liver Disease. Am J Gastroenterol. 2017 Apr; 112: (4)652-653.
    View PubMed
  17. Haffar S, Bazerbachi F, Prokop L, Watt KD, Murad MH, Chari ST. Frequency and prognosis of acute pancreatitis associated with fulminant or non-fulminant acute hepatitis A: A systematic review. Pancreatology. 2017 Mar - Apr; 17 (2):166-175 Epub 2017 Feb 17
    View PubMed
  18. Nicolas CT, Nyberg SL, Heimbach JK, Watt K, Chen HS, Hathcock MA, Kremers WK. Liver transplantation after share 35: Impact on pretransplant and posttransplant costs and mortality. Liver Transpl. 2017 Jan; 23 (1):11-18 Epub 2016 Dec 05
    View PubMed
  19. Nicolas CT, Nyberg SL, Heimbach JK, Watt K, Chen HS, Hathcock MA, Kremers WK. Liver transplantation after share 35: Impact on pretransplant and posttransplant costs and mortality Liver Transplantation. 2017; 23: (1)11-8.
  20. Watt KD. The evolving role of the microbiome in liver failure and liver transplantation. Liver Transpl. 2016 Nov; 22: (S1)58-61.
    View PubMed
  21. Kasraianfard A, Watt KD, Lindberg L, Alexopoulos S, Rezaei N. HBIG Remains Significant in the Era of New Potent Nucleoside Analogues for Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation. Int Rev Immunol. 2016 Jul 3; 35: (4)312-324.
    View PubMed
  22. Doycheva I, Amer S, Watt KD. De Novo Malignancies After Transplantation: Risk and Surveillance Strategies. Med Clin North Am. 2016 May; 100: (3)551-67.
    View PubMed
  23. Malhi H, Allen AM, Watt KD. Nonalcoholic fatty liver: optimizing pretransplant selection and posttransplant care to maximize survival. Curr Opin Organ Transplant. 2016 Apr; 21: (2)99-106.
    View PubMed
  24. Doycheva I, Leise MD, Watt KD. The Intestinal Microbiome and the Liver Transplant Recipient: What We Know and What We Need to Know. Transplantation. 2016 Jan; 100: (1)61-8.
    View PubMed
  25. Dhanasekaran R, Sanchez W, Mounajjed T, Wiesner RH, Watt KD, Charlton MR. Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence. Liver Int. 2015 Nov; 35: (11)2433-41.
    View PubMed
  26. Fussner LA, Iyer VN, Cartin-Ceba R, Lin G, Watt KD, Krowka MJ. Intrapulmonary vascular dilatations are common in portopulmonary hypertension and may be associated with decreased survival. Liver Transpl. 2015 Nov; 21: (11)1355-64.
    View PubMed
  27. Watt KD. Keys to long-term care of the liver transplant recipient. Nat Rev Gastroenterol Hepatol. 2015 Nov; 12: (11)639-48.
    View PubMed
  28. Aqel BA, Pungpapong S, Leise M, Werner KT, Chervenak AE, Watt KD, Murphy JL, Ryland K, Keaveny AP, McLemore R, Vargas HE. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis. Hepatology. 2015 Oct; 62 (4):1004-12 Epub 2015 Aug 07
    View PubMed
  29. Gunneson T, Johnson B, Findlay J, Joyner M, Watt KD. Comparing Cardiopulmonary Exercise Testing in End-Stage Liver Disease Patients. Transplant Proc. 2015 Oct; 47: (8)2470-2.
    View PubMed
  30. Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS Jr, Fried MW, Terrault NA, O'Leary JG, Vargas HE, Kuo A, Schiff E, Sulkowski MS, Gilroy R, Watt KD, Brown K, Kwo P, Pungpapong S, Korenblat KM, Muir AJ, Teperman L, Fontana RJ, Denning J, Arterburn S, Dvory-Sobol H, Brandt-Sarif T, Pang PS, McHutchison JG, Reddy KR, Afdhal N, SOLAR-1 Investigators. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology. 2015 Sep; 149 (3):649-59 Epub 2015 May 15
    View PubMed
  31. Fussner LA, Heimbach JK, Fan C, Dierkhising R, Coss E, Leise MD, Watt KD. Cardiovascular disease after liver transplantation: When, What, and Who Is at Risk. Liver Transpl. 2015 Jul; 21: (7)889-96.
    View PubMed
  32. Bhat M, Watt KD. Mammalian target of rapamycin inhibition after solid organ transplantation: can it, and does it, reduce cancer risk? Clin Transplant. 2015 Jul; 29: (7)654-63.
    View PubMed
  33. Pungpapong S, Aqel B, Leise M, Werner KT, Murphy JL, Henry TM, Ryland K, Chervenak AE, Watt KD, Vargas HE, Keaveny AP. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology. 2015 Jun; 61(6):1880-6. Epub 2015 Apr 27.
    View PubMed
  34. Sarkar M, Watt KD, Terrault N, Berenguer M. Outcomes in liver transplantation: does sex matter? J Hepatol. 2015 Apr; 62: (4)946-55.
    View PubMed
  35. Watt KD. Is 40 the new 30? Transpl Int. 2015 Feb; 28(2):146-7.
    View PubMed
  36. Pestana L, Swain J, Dierkhising R, Kendrick ML, Kamath PS, Watt KD. Bariatric surgery in patients with cirrhosis with and without portal hypertension: a single-center experience. Mayo Clin Proc. 2015 Feb; 90(2):209-15.
    View PubMed
  37. Koning L, Charlton MR, Pas SD, Heimbach JK, Osterhaus AD, Watt KD, Janssen HL, de Knegt RJ, van der Eijk AA. Prevalence and clinical consequences of Hepatitis E in patients who underwent liver transplantation for chronic Hepatitis C in the United States. BMC Infect Dis. 2015; 15:371.
    View PubMed
  38. Fussner LA, Charlton MR, Heimbach JK, Fan C, Dierkhising R, Coss E, Watt KD. The impact of gender and NASH on chronic kidney disease before and after liver transplantation. Liver Int. 2014 Sep; 34(8):1259-66. Epub 2013 Nov 21.
    View PubMed
  39. Watt KD, Fan C, Therneau T, Heimbach JK, Seaberg EC, Charlton MR. Serum adipokine and inflammatory markers before and after liver transplantation in recipients with major cardiovascular events. Liver Transpl. 2014 Jul; 20: (7)791-7.
    View PubMed
  40. Kim DJ, Clark PJ, Heimbach J, Rosen C, Sanchez W, Watt K, Charlton MR. Recurrence of hepatocellular carcinoma: Importance of mRECIST response to chemoembolization and tumor size. Am J Transplant. 2014; 14(6):1383-90.
    View PubMed
  41. Duarte-Rojo A, Budhraja V, Veldt BJ, Goldstein DD, Watt KD, Heimbach JK, McHutchison JG, Tillman HL, Poterucha JJ, Charlton MR. Interleukin-28B and fibrosing cholestatic hepatitis in posttransplant hepatitis C: a case-control study and literature review. Liver Transpl. 2013 Dec; 19(12):1311-7.
    View PubMed
  42. Watt KD. Extrahepatic implications of metabolic syndrome. Liver Transpl. 2013 Nov; 19 Suppl 2:S56-61.
    View PubMed
  43. Guichelaar MM, Gawrieh S, Olivier M, Viker K, Krishnan A, Sanderson S, Malinchoc M, Watt KD, Swain JM, Sarr M, Charlton MR. Interactions of allelic variance of PNPLA3 with nongenetic factors in predicting nonalcoholic steatohepatitis and nonhepatic complications of severe obesity. Obesity (Silver Spring). 2013 Sep; 21: (9)1935-41.
    View PubMed
  44. Watt KD, Dierkhising R, Fan C, Heimbach JK, Tillman H, Goldstein D, Thompson A, Krishnan A, Charlton MR. Investigation of PNPLA3 and IL28B genotypes on diabetes and obesity after liver transplantation: insight into mechanisms of disease. Am J Transplant. 2013 Sep; 13(9):2450-7. Epub 2013 Jul 16.
    View PubMed
  45. Singal AK, Kamath PS, Francisco Ziller N, DiCecco S, Shoreibah M, Kremers W, Charlton MR, Heimbach JK, Watt KD, Shah VH. Nutritional status of patients with alcoholic cirrhosis undergoing liver transplantation: time trends and impact on survival. Transpl Int. 2013 Aug; 26: (8)788-94.
    View PubMed
  46. Heimbach JK, Watt KD, Poterucha JJ, Ziller NF, Cecco SD, Charlton MR, Hay JE, Wiesner RH, Sanchez W, Rosen CB, Swain JM. Combined liver transplantation and gastric sleeve resection for patients with medically complicated obesity and end-stage liver disease. Am J Transplant. 2013 Feb; 13(2):363-8. Epub 2012 Nov 08.
    View PubMed
  47. Watt KD. Reducing the load: the evolution and management of obesity and nonalcoholic steatohepatitis before liver transplantation. Liver Transpl. 2012 Nov; 18 Suppl 2:S52-8.
    View PubMed
  48. Chandok N, Watt KD. Burden of de novo malignancy in the liver transplant recipient. Liver Transpl. 2012 Nov; 18(11):1277-89. Epub 2012 Sep 26.
    View PubMed
  49. Watt KD, Dierkhising R, Heimbach JK, Charlton MR. Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: an analysis of the Scientific Registry of Transplant Recipients Database. Liver Transpl. 2012 Sep; 18(9):1029-36.
    View PubMed
  50. Singh S, Watt KD. Long-term medical management of the liver transplant recipient: what the primary care physician needs to know. Mayo Clin Proc. 2012 Aug; 87(8):779-90. Epub 2012 Jul 03.
    View PubMed
  51. Duarte-Rojo A, Veldt BJ, Goldstein DD, Tillman HL, Watt KD, Heimbach JK, McHutchison JG, Poterucha JJ, Vargas-Vorackova F, Charlton MR. The course of posttransplant hepatitis C infection: comparative impact of donor and recipient source of the favorable IL28B genotype and other variables. Transplantation. 2012 Jul 27; 94(2):197-203.
    View PubMed
  52. Levitsky J, Fiel MI, Norvell JP, Wang E, Watt KD, Curry MP, Tewani S, McCashland TM, Hoteit MA, Shaked A, Saab S, Chi AC, Tien A, Schiano TD. Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. Gastroenterology. 2012 May; 142(5):1132-1139.e1. Epub 2012 Jan 25.
    View PubMed
  53. Laryea MA, Watt KD. Immunoprophylaxis against and prevention of recurrent viral hepatitis after liver transplantation. Liver Transpl. 2012 May; 18(5):514-23.
    View PubMed
  54. Veldt BJ, Duarte-Rojo A, Thompson AJ, Watt KD, Heimbach JK, Tillmann HL, Goldstein DD, McHutchison JG, Charlton MR. Recipient IL28B polymorphism is an important independent predictor of posttransplant diabetes mellitus in liver transplant patients with chronic hepatitis C. Am J Transplant. 2012 Mar; 12(3):737-44. Epub 2012 Feb 02.
    View PubMed
  55. Koehler E, Swain J, Sanderson S, Krishnan A, Watt K, Charlton M. Growth hormone, dehydroepiandrosterone and adiponectin levels in non-alcoholic steatohepatitis: an endocrine signature for advanced fibrosis in obese patients. Liver Int. 2012 Feb; 32: (2)279-86.
    View PubMed
  56. Weingarten TN, Mantilla CB, Swain JM, Kendrick ML, Oberhansley JM, Burcham RJ, Ribeiro TC, Watt KD, Schroeder DR, Narr BJ, Sprung J. Nonalcoholic steatohepatitis in bariatric patients with a diagnosis of obstructive sleep apnea. Obes Facts. 2012; 5(4):587-96. Epub 2012 Sep 05.
    View PubMed
  57. Watt KD. Metabolic syndrome: is immunosuppression to blame? Liver Transpl. 2011 Nov; 17 Suppl 3:S38-42.
    View PubMed
  58. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. 2011 Oct; 141: (4)1249-53.
    View PubMed
  59. Massoud O, Heimbach J, Viker K, Krishnan A, Poterucha J, Sanchez W, Watt K, Wiesner R, Charlton M. Noninvasive diagnosis of acute cellular rejection in liver transplant recipients: a proteomic signature validated by enzyme-linked immunosorbent assay. Liver Transpl. 2011 Jun; 17(6):723-32.
    View PubMed
  60. Ribeireiro T, Swain J, Sarr M, Kendrick M, Que F, Sanderson S, Krishnan A, Viker K, Watt K, Charlton M. NAFLD and insulin resistance do not increase the risk of postoperative complications among patients undergoing bariatric surgery--a prospective analysis. Obes Surg. 2011 Mar; 21 (3):310-5
    View PubMed
  61. Coss E, Watt KD, Pedersen R, Dierkhising R, Heimbach JK, Charlton MR. Predictors of cardiovascular events after liver transplantation: a role for pretransplant serum troponin levels. Liver Transpl. 2011 Jan; 17(1):23-31.
    View PubMed
  62. Makol A, Watt KD, Chowdhary VR. Autoimmune hepatitis: a review of current diagnosis and treatment. Hepat Res Treat. 2011; 2011:390916.
    View PubMed
  63. Watt KD. Obesity and metabolic complications of liver transplantation. Liver Transpl. 2010 Oct; 16(S2):S65-71.
    View PubMed
  64. Watt KD, Coss E, Pedersen RA, Dierkhising R, Heimbach JK, Charlton MR. Pretransplant serum troponin levels are highly predictive of patient and graft survival following liver transplantation. Liver Transpl. 2010 Aug; 16(8):990-8.
    View PubMed
  65. Watt KD, Charlton MR. Metabolic syndrome and liver transplantation: a review and guide to management. J Hepatol. 2010 Jul; 53(1):199-206. Epub 2010 Mar 31.
    View PubMed
  66. Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Charlton MR. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant. 2010 Jun; 10: (6)1420-7.
    View PubMed
  67. Chandok N, Watt KD. Pain management in the cirrhotic patient: the clinical challenge. Mayo Clin Proc. 2010 May; 85(5):451-8. Epub 2010 Mar 31.
    View PubMed
  68. Watt KDS, Chandok N. Safe use of opioids to manage pain in patients with cirrhosis: Reply. Mayo Clin Proc. 2010; 85(10):960.
  69. Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Sanchez W, Gores GJ. Long-term probability of and mortality from de novo malignancy after liver transplantation. Gastroenterology. 2009 Dec; 137: (6)2010-7.
    View PubMed
  70. Koehler E, Watt K, Charlton M. Fatty liver and liver transplantation. Clin Liver Dis. 2009 Nov; 13(4):621-30.
    View PubMed
  71. Watt K, Veldt B, Charlton M. A practical guide to the management of HCV infection following liver transplantation. Am J Transplant. 2009 Aug; 9: (8)1707-13.
    View PubMed
  72. Veldt BJ, Poterucha JJ, Watt KD, Wiesner RH, Hay JE, Rosen CB, Heimbach JK, Janssen HL, Charlton MR. Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C. Am J Transplant. 2009 Jun; 9(6):1406-13. Epub 2009 May 13.
    View PubMed
  73. Veldt BJ, Poterucha JJ, Watt KD, Wiesner RH, Hay JE, Kremers WK, Rosen CB, Heimbach JK, Charlton MR. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transplant. 2008 Nov; 8: (11)2426-33.
    View PubMed
  74. Nudo CG, Yoshida EM, Bain VG, Marleau D, Wong P, Marotta PJ, Renner E, Watt KD, Deschenes M. Liver transplantation for hepatic epithelioid hemangioendothelioma: the Canadian multicentre experience. Can J Gastroenterol. 2008 Oct; 22(10):821-4.
    View PubMed
  75. Leonard J, Heimbach JK, Malinchoc M, Watt K, Charlton M. The impact of obesity on long-term outcomes in liver transplant recipients-results of the NIDDK liver transplant database. Am J Transplant. 2008 Mar; 8: (3)667-72.
    View PubMed
  76. Watt KD, Burak KW, Deschenes M, Lilly L, Marleau D, Marotta P, Mason A, Peltekian KM, Renner E, Yoshida EM, Canadian Transplant Hepatology Outcomes Research Network. Survival after liver transplantation for hepatitis C is unchanged over two decades in Canada. Can J Gastroenterol. 2008 Feb; 22(2):153-4.
    View PubMed
  77. McCashland T, Watt K, Lyden E, Adams L, Charlton M, Smith AD, McGuire BM, Biggins SW, Neff G, Burton JR Jr, Vargas H, Donovan J, Trotter J, Faust T. Retransplantation for hepatitis C: results of a U.S. multicenter retransplant study. Liver Transpl. 2007 Sep; 13(9):1246-53.
    View PubMed
  78. Laryea M, Watt KD, Molinari M, Walsh MJ, McAlister VC, Marotta PJ, Nashan B, Peltekian KM. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transpl. 2007 Aug; 13(8):1109-14.
    View PubMed
  79. Watt K, Kives K, Corbin I, Zhang M, Minuk GY. Lack of susceptibility to ischemic necrosis of the remnant liver following partial hepatectomy in the rat. Hepatogastroenterology. 2007 Mar; 54(74):463-5.
    View PubMed
  80. Tulisov A, McMahon BJ, Koch A, Minuk G, Chulanov V, Bruce MG, Uhanova J, Borresen M, Williams J, Osiowy C, Gelvan A, Alexeeva M, Larke B, Watt K. Viral hepatitis in the Arctic. A review from a Circumpolar Workshop on Viral hepatitis, ICCH13. Alaska Med. 2007; 49(2 Suppl):193-203.
    View PubMed
  81. Molinari M, Watt KD, Kruszyna T, Nelson R, Walsh M, Huang WY, Nashan B, Peltekian K. Acute liver failure induced by green tea extracts: case report and review of the literature. Liver Transpl. 2006 Dec; 12(12):1892-5.
    View PubMed
  82. Watt KD. Abnormal liver enzymes 2-3 months after liver transplantation in a patient with hepatitis C: Report of a case. Liver Transpl. 2006 Nov; 12(11 Suppl 2):S29-31.
    View PubMed
  83. Watt KD, Burak K, Deschenes M, Lilly L, Marleau D, Marotta P, Mason A, Peltekian KM, Renner EL, Yoshida EM, Canadian Transplant Hepatology Outcomes Research Network. Recurrent hepatitis C post-transplantation: where are we now and where do we go from here? A report from the Canadian transplant hepatology workshop. Can J Gastroenterol. 2006 Nov; 20(11):725-34.
    View PubMed
  84. Singh H, Watt K, Veitch R, Cantor M, Duerksen DR. Malnutrition is prevalent in hospitalized medical patients: are housestaff identifying the malnourished patient? Nutrition. 2006 Apr; 22(4):350-4. Epub 2006 Feb 02.
    View PubMed
  85. Watt KD, Lyden ER, Gulizia JM, McCashland TM. Recurrent hepatitis C posttransplant: early preservation injury may predict poor outcome. Liver Transpl. 2006 Jan; 12(1):134-9.
    View PubMed
  86. Watt KD, Menke T, Lyden E, McCashland TM. Mortality while awaiting liver retransplantation: predictability of MELD scores. Transplant Proc. 2005 Jun; 37(5):2172-3.
    View PubMed
  87. Watt KD, McCashland TM. Transplantation in the alcoholic patient. Semin Liver Dis. 2004 Aug; 24(3):249-55.
    View PubMed
  88. Watt K, Uhanova J, Gong Y, Kaita K, Doucette K, Pettigrew N, Minuk GY. Serum immunoglobulins predict the extent of hepatic fibrosis in patients with chronic hepatitis C virus infection. J Viral Hepat. 2004 May; 11(3):251-6.
    View PubMed
  89. Belitsky P, Nashan B, Kiberd B, West K, Legare JF, Keough-Ryan T, Watt K. The year in review--2004. Clin Transpl. 2004; 269-301.
    View PubMed
  90. Watt KD, Lyden ER, McCashland TM. Poor survival after liver retransplantation: is hepatitis C to blame? Liver Transpl. 2003 Oct; 9(10):1019-24.
    View PubMed
  91. Watt K, Uhanova J, Minuk GY. Hepatorenal syndrome: diagnostic accuracy, clinical features, and outcome in a tertiary care center. Am J Gastroenterol. 2002 Aug; 97(8):2046-50.
    View PubMed